Clinical Trials Logo

Rheumatic Diseases clinical trials

View clinical trials related to Rheumatic Diseases.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06302218 Not yet recruiting - Knee Osteoarthritis Clinical Trials

ESPB vs iPACK+ACB in Total Knee Arthroplasty

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Effect of iPACK block with Adductor Canal Block and ESPB on pain management, and NLR and PLR following knee arthroplasty

NCT ID: NCT06273306 Not yet recruiting - Clinical trials for Arthritis, Rheumatoid

Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC)

IMIDOC
Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The main objective is to evaluate the implementation of a hybrid care model called the mixed attention model (MAM) in clinical practice and to evaluate whether its implementation improves clinical outcomes compared to conventional follow-up. This is a multicenter prospective observational study involving 360 patients with rheumatoid arthritis (RA) and Spondylarthritis (SpA) from five Spanish Hospitals. Patients will be followed-up by the MAM protocol, which is a care model that incorporates the use of digital tool consisting of a mobile application (App) that patients can use at home and that professionals can review asynchronously to detect incidents and to follow their patients; clinical evolution between face-to-face visits. Another group of patients, whose follow-up will be conducted in accordance with a traditional face-to-face care model, will be assessed as the control group. Sociodemographic characteristics, treatments, laboratory parameters, assessment of tender and swollen joints, visual analogue scale for pain and electronic patient reported outcome reports (ePROs) will be collected for all subjects. In the MAM group, these items will be self-assessed both by the mobile App and during face-to-face visits with rheumatologist, who will do the same for patients included in the traditional care model. Patients will be able to report any incidence related to their disease or treatment through the mobile App.

NCT ID: NCT06097585 Not yet recruiting - Heart Failure Clinical Trials

Gliflozins on HF in Regurgitant Rheumatic Heart

Start date: December 1, 2023
Phase:
Study type: Observational

The objective of this trial is to detect impact of Gliflozin on patients with heart failure due to reurgitant rheumatic valve disease

NCT ID: NCT06059430 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Cohort Project of Patients With Inflammatory Rheumatism

SMAP
Start date: September 20, 2023
Phase:
Study type: Observational

Chronic inflammatory rheumatism (CIR) is a group of inflammatory diseases that affect the joints and spine and are related to an abnormal immune response. CIR includes many different forms of arthritis that manifest as painful and swollen joints, stiffness, especially in the morning and persisting even after exercise, and limited joint mobility. CIR can also affect bones, cartilage, ligaments, tendons and muscles. Some may affect other organs. These symptoms can lead to a reduced quality of life, limited physical activity and progressive structural and functional deterioration of the joints. Current treatment for CIR is aimed at reducing inflammation and relieving pain. Anti-inflammatory medications such as corticosteroids and non-steroidal anti-inflammatory drugs can be used to relieve pain and inflammation. Biotherapies can also be used to modify the progression of the disease. On the other hand, regular exercise can help strengthen the muscles that support the affected joints and improve mobility. Physical therapies, such as physical and occupational therapy, can also help improve mobility and relieve pain. Although there is no definitive cure for CIR early and appropriate treatment can help reduce symptoms and improve quality of life, as well as avoid the risk of developing complications such as lung, cardiovascular, kidney, ophthalmic, liver and other diseases. It is in this context, in order to better understand CIR to improve the global management of patients, and to analyze the evolution of CIR over time in relation to the different treatments proposed, that the interest in creating a database of patients with CIR arises.

NCT ID: NCT05821335 Not yet recruiting - Rehabilitation Clinical Trials

Leap Motion Based Gamefication Exercises in the Individuals With Systemic Sclerosis

Start date: May 30, 2023
Phase: N/A
Study type: Interventional

Leap Motion Based Gamefication Exercises in the Individuals With Systemic Sclerosis

NCT ID: NCT05682196 Not yet recruiting - Clinical trials for Rheumatic Heart Disease in Children

Rituximab in Patients With Acute Rheumatic Fever

AGRAF-2
Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Acute Rheumatic Fever is an autoimmune inflammatory post-infectious syndrome, mainly caused by type A streptococcus. It is characterized as an inadequate immune response. It may provoke carditis, combined with articular, skin and neurologic signs. Only carditis, prevalent in 60% of acute rheumatic diseases, may provoke valvular sequels, which define rheumatic cardiopathy. Antibiotherapy based on penicillin is the standard treatment of both acute rheumatic fever and its prevention. Although no anti-inflammatory treatment has proved its efficacy, with or without steroids anti-inflammatory treatments are administered in acute episode of ARF. Up to date, only prevention strategies have shown efficacy.

NCT ID: NCT05618223 Not yet recruiting - Heart Failure Clinical Trials

Dapagliflozin Effect on Rheumatic Mitral Stenosis

Dapa-Rhemis
Start date: December 1, 2022
Phase: Phase 3
Study type: Interventional

Rheumatic mitral stenosis remains a health problem in developing countries. Progressive fibrosis of the valves and myocardium is the main pathophysiology that plays an important role. Dapagliflozin has various beneficial effects on the heart by reducing fibrosis, reducing inflammation, and improving patient quality of life. However, the role of this therapy is unknown in patients with rheumatic mitral stenosis.

NCT ID: NCT05465356 Not yet recruiting - Rheumatic Disease Clinical Trials

Patient Engagement With Digital Health Tools in Rheumatology

Start date: July 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate the patient engagement with digital tools for diagnosis and monitoring of disease in rheumatology services

NCT ID: NCT05417477 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Evaluation of a Connected Interface to Improve the Quality of Life and the Disability of Patient With Rheumatic Diseases

RHUMATO-APP
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Musculoskeletal pathologies constitute a major public health problem. Rheumatologists, whether they practice in private or hospital settings, play a major role in the management of responsible for these ailments. Due to the increase in life expectancy, an increase in the number of consultations can be expected. It is therefore imperative that the latter be more efficient, without losing quality. Communication between doctor and patient is bound to evolve due to the multiplicity of IT tools available and those that are emerging, which are increasingly essential, including many smartphone applications. Each targeting a specific pathology (rheumatoid arthritis, ankylosing spondylitis, osteoporosis osteoarthritis, they will allow the patient to self-assess, thus becoming an actor in his own care. A "facilitated" exchange between caregivers and patients would be relevant and would provide added value for all. This is the reason why there is a real need for an application listing precise information on the patient, in a sufficiently succinct way to optimize their transmission to the physiotherapist.

NCT ID: NCT05270590 Not yet recruiting - Clinical trials for Rheumatic Mitral Valve Disease

Minimally Invasive Rheumatic Mitral Valve Surgery

Start date: March 1, 2022
Phase:
Study type: Observational

Early outcome of minimally invasive rheumatic mitral valve surgery through periareolar versus submamary approach